NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) Drug Patent Profile
✉ Email this page to a colleague
When do Nitrofurantoin (monohydrate/macrocrystals) patents expire, and when can generic versions of Nitrofurantoin (monohydrate/macrocrystals) launch?
Nitrofurantoin (monohydrate/macrocrystals) is a drug marketed by Alvogen, Amneal Pharms, Aurobindo Pharma, Aurobindo Pharma Usa, Inventia, Mankind Pharma, Omsav Pharma, Ranbaxy Labs Ltd, Sandoz, Sunny, and Watson Labs Inc. and is included in eleven NDAs.
The generic ingredient in NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) is nitrofurantoin; nitrofurantoin, macrocrystalline. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the nitrofurantoin; nitrofurantoin, macrocrystalline profile page.
Summary for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 29 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 4 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) at DailyMed |
Recent Clinical Trials for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Saltro | Phase 3 |
MJM Bonten | Phase 3 |
ZonMw: The Netherlands Organisation for Health Research and Development | Phase 3 |
See all NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) clinical trials
Pharmacology for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Drug Class | Nitrofuran Antibacterial |